UNSPSC 51181906: Urofollitropin

This classification denotes a therapeutic follicle stimulating hormone with the molecular formula C975H1513N267O304S26, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W9BB98U6HP, more generally known as urofollitropin. European Medicines Agency schedules urofollitropin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05053MIG. The term UROFOLLITROPIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 1, no. 4, 1987, list 27.

UNSPSC 51181906 Urofollitropin, a Commodity code, encompasses pharmaceutical products that state and local governments procure through cooperative purchasing vehicles and multi-source generic drug contracts. The code captures individual pharmaceutical line items — in this case, urofollitropin, a fertility medication — that are sourced and distributed to state and local health facilities, including state hospitals, clinics, and other government healthcare operations. State and local buyers typically acquire such pharmaceuticals in bulk through master agreements negotiated by cooperative purchasing alliances, which establish pricing, supply chain relationships, and compliance frameworks for dozens or hundreds of therapeutic categories across multiple participating jurisdictions. Issuing bodies include state departments of health and administration (often through cooperative purchasing offices), county health departments, and municipal healthcare facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary vehicle for such procurement.

The most recent relevant opportunity shows MMCAP issuing an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across Minnesota, Oregon, and participating member jurisdictions. The procurement requires manufacturers to provide comprehensive pricing for identified pharmaceutical products with specific National Drug Codes (NDCs), with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and the remainder on administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors must maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and carry commercial general liability insurance of $5,000,000 per occurrence. Awarded vendors' products become effective July 1, 2026, with a two-year initial term and optional extensions; no specific award values are disclosed, but vendors face performance penalties of $200 to $1,500 per violation for late reporting or missed compliance deadlines.